At exposures 8 times greater than those acclimated in humans, liraglutide acquired a statistically cogent access in thyroid tumors in rats. The analytic appliance of these allegation is unknown.
The FDA said serum calcitonin, a biomarker of medullary thyroid cancer, was hardly added in liraglutide patients, but still aural accustomed ranges, and it appropriate advancing ecology for 15 years in a blight registry.
The sole being in the comparator accumulation and four of the 5 bodies in the liraglutide accumulation had serum markers (elevated calcitonin) evocative of above-mentioned ache at baseline.
more about: Liraglutide
from: Pharmaceutical Ingredients
No comments:
Post a Comment